Covalon Technologies Ltd. is an advanced medical biosystems company that has developed and patented advanced therapeutic biomaterials for wound care and surgical applications and coatings. Polymer chemistry and surface coating technology have been combined to create a range of time-release drug delivery platforms that are applied to many medical devices to treat many critical conditions. A variety of applications for these technologies have been identified and specific products have been developed. The products offer features and benefits providing solutions to many of the problems caused by current devices and their material properties which are used by most medical device manufacturers and suppliers. The problems include infection, poor biocompatibility, and microbial attachment. 

Covalon was recognized as a TSX Venture 50™ company in both 2008 and 2007. The TSX Venture 50 are the top 10 companies in each of five major industry sectors - mining, oil & gas, technology & life sciences, diversified industries and cleantech - based on a ranking formula with equal weighting given to one-year revenue (last reported 12 months), return on investment, market cap growth and trading volume. All data was as of December 31, 2007 and December 31, 2006, respectively.

^{_{TSX Venture 50 is a trade-mark of TSX Inc. and is used under license.}} 

Our Mission              

Covalon's mission is to apply Covalon's proprietary technology platforms for advanced coatings and biomatrices to all medical devices, surgical products and wound care applications where the technologies offer a strategic advantage to medical practice; the goal will be achieved by exhibiting a professional approach through customer-driven long term relationships.

     ^{Covalon is an
     ISO 13485:2003
     registered company.}